Research Analysts Offer Predictions for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at William Blair lifted their Q2 2025 EPS estimates for Biogen in a note issued to investors on Wednesday, February 12th. William Blair analyst M. Minter now forecasts that the biotechnology company will earn $4.20 per share for the quarter, up from their prior estimate of $3.79. William Blair has a “Outperform” rating on the stock. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share. William Blair also issued estimates for Biogen’s Q1 2026 earnings at $3.86 EPS, Q2 2026 earnings at $4.31 EPS, FY2026 earnings at $15.20 EPS and FY2028 earnings at $18.33 EPS.

A number of other brokerages have also recently commented on BIIB. Barclays reduced their target price on shares of Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a report on Thursday, October 31st. StockNews.com lowered Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 28th. Canaccord Genuity Group lowered their target price on Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday. Royal Bank of Canada reduced their price target on Biogen from $231.00 to $225.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Wolfe Research started coverage on Biogen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Biogen presently has an average rating of “Hold” and an average target price of $211.96.

Biogen Price Performance

NASDAQ BIIB opened at $137.33 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. Biogen has a 1-year low of $128.51 and a 1-year high of $238.00. The stock has a market capitalization of $20.01 billion, a price-to-earnings ratio of 12.41, a PEG ratio of 1.65 and a beta of -0.08. The business’s fifty day moving average price is $146.90 and its 200-day moving average price is $172.99.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%.

Institutional Trading of Biogen

A number of institutional investors have recently added to or reduced their stakes in BIIB. Larson Financial Group LLC boosted its holdings in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 141 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Biogen during the 4th quarter valued at approximately $25,000. OFI Invest Asset Management purchased a new position in shares of Biogen during the 4th quarter valued at approximately $32,000. Ashton Thomas Securities LLC acquired a new stake in shares of Biogen during the third quarter worth approximately $33,000. Finally, SRS Capital Advisors Inc. bought a new stake in shares of Biogen in the fourth quarter worth $33,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.